secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEKTAR THERAPEUTICS (NKTR)
CIK:        0000906709
Form:       8-K
Filed at:   2026-02-13T23:59:59+00:00
Accession:  0001193125-26-049378
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nektar Therapeutics prices upsized $400M public offering of common stock and pre-funded warrants
--------------------------------------------------------------------------------

- Offering of 6,603,449 common shares at $58.00 and 293,103 pre-funded warrants at $57.9999; gross proceeds $400M.
- Underwriters exercised full option for 1,034,482 additional shares; net proceeds ~$432M after discounts/expenses.
- Proceeds for general corporate purposes including Phase 3 trial for rezpegaldesleukin and manufacturing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/906709/000119312526049378/0001193125-26-049378-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/906709/000119312526049378/d66289d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-049378

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer